Database : MEDLINE
Search on : D02.455.426.559.389.097.120 [DeCS Category]
References found : 227 [refine]
Displaying: 1 .. 10   in format [Large]

page 1 of 23 go to page                         

  1 / 227 MEDLINE  
              next record last record
select
to print
Photocopy
Full text
PMID:28793297
Author:Voabil P; Liberal J; Leal EC; Bauer J; Cunha-Vaz J; Santiago AR; Ambrósio AF
Address:Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Title:Calcium Dobesilate Is Protective against Inflammation and Oxidative/Nitrosative Stress in the Retina of a Type 1 Diabetic Rat Model.
Source:Ophthalmic Res; 58(3):150-161, 2017.
ISSN:1423-0259
Country of publication:Switzerland
Language:eng
Abstract:Calcium dobesilate (CaD) has been prescribed to some patients in the early stages of diabetic retinopathy to delay its progression. We previously reported that the treatment of diabetic animals (4 weeks of diabetes) with CaD, during the last 10 days of diabetes, prevents blood-retinal barrier breakdown. Here, we aimed to investigate whether later treatment of diabetic rats with CaD would reverse inflammatory processes in the retina. Diabetes was induced with streptozotocin, and 6 weeks after diabetes onset, CaD (100 mg/kg/day) was administered for 2 weeks. The treatment with CaD significantly increased glial fibrillary acidic protein (GFAP) levels in the retina of nondiabetic animals (138.6 ± 12.8% of control) and enhanced the diabetes-induced increase in GFAP levels (174.8 ± 5.6% of control). In addition, CaD prevented the increase in mRNA and protein expression of tumor necrosis factor and interleukin-1ß, as well as the formation of oxidized carbonyl residues and the increase in nitrotyrosine immunoreactivity, particularly in the ganglion cell layer of diabetic animals. We demonstrate that the treatment of diabetic animals with CaD can reverse the established proinflammatory processes in the retina. These beneficial effects appear to be attributed, at least partially, to the antioxidant properties of CaD.
Publication type:JOURNAL ARTICLE
Name of substance:0 (Hemostatics); 5921X1560Q (Calcium Dobesilate)


  2 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:28151018
Author:Cai T; Wu XY; Zhang XQ; Shang HX; Zhang ZW; Liao L; Dong JJ
Address:1 Department of Medicine, Division of Traditional Chinese Medicine, Tai'an Hospital of Traditional Chinese Medicine , Tai'an, China .
Title:Calcium Dobesilate Prevents Diabetic Kidney Disease by Decreasing Bim and Inhibiting Apoptosis of Renal Proximal Tubular Epithelial Cells.
Source:DNA Cell Biol; 36(4):249-255, 2017 Apr.
ISSN:1557-7430
Country of publication:United States
Language:eng
Abstract:Apoptosis of renal proximal tubular epithelial cells (PTECs) plays a vital role in the pathogenesis and progression of diabetic kidney disease (DKD). Calcium dobesilate is a vascular protective compound used for treatment of diabetic retinopathy and chronic venous insufficiency. The aim of this study was to determine whether calcium dobesilate can protect PTECs from glucose-induced apoptosis and the potential mechanism of this effect. It is indicated that high glucose promoted abnormal apoptosis of HK2 cells, which was inhibited by treatment of calcium dobesilate, while Bim expression decreased in response to calcium dobesilate in high-glucose-treated HK2 cells. These findings confirmed the therapeutic effects of calcium dobesilate on DKD and emphasized the importance of it as a potentially crucial drug in treatment of DKD.
Publication type:JOURNAL ARTICLE
Name of substance:0 (Bcl-2-Like Protein 11); 5921X1560Q (Calcium Dobesilate); IY9XDZ35W2 (Glucose)


  3 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:27911427
Author:Vorob'eva IV
Address:Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation, 2/1 Barrikadnaya St., Moscow, Russian Federation, 123995; S.P. Botkin State Clinical Hospital, Branch #1, Moscow Department of Public Health, 7 Mamonovskiy pereulok, Moscow, Russian Federation, 123001.
Title:Sovremennye podkhody k rannei diagnostike, patogeneticheskomu lecheniyu diabeticheskoi retinopatii. [Modern approach to early diagnosis and pathogenetic treatment of diabetic retinopathy].
Source:Vestn Oftalmol; 132(5):60-67, 2016.
ISSN:0042-465X
Country of publication:Russia (Federation)
Language:rus
Abstract:AIM: To improve the approach to pathogenetic treatment of diabetic retinopathy (DR) through early diagnosis and a new method for predicting disease progression. MATERIAL AND METHODS: The study enrolled 330 type 2 diabetes patients with DR (660 eyes), of whom women constituted 64.6%, men - 35.4%. The mean patient age was 62.3±2.3 years. Three groups were formed: the controls - 30 healthy volunteers (60 eyes) and 30 type 2 diabetes patients without ocular involvement (DR 0, 60 eyes); group 1 - 30 type 2 diabetes patients with DR I but no diabetic macular edema (DR I without DME, 60 eyes) that were treated with calcium dobesilate; group 2 - 240 type 2 diabetes patients, who had diabetic retinopathy of different stages (DR I, II, or III with DME, 480 eyes) and received laser retinal photocoagulation (LRP). The groups were all alike in terms of sex and age distribution. All patients underwent ophthalmic examination, including best corrected visual acuity (BCVA) and critical flicker fusion frequency (CFFF) testing, tonometry, biomicroscopy, MAIA fundus microperimetry, optical coherence tomography (OCT), and fluorescein angiography (FAG) of the retina. Traditionally we also determined blood sugar and glycated hemoglobin levels as well as vascular endothelial growth factor (VEGF-A) and monocyte chemoattractant protein (MCP-1) in tear fluid by ELISA. RESULTS: In group 1, which was under conservative therapy with calcium dobesilate, there was an increase in BCVA by the average of 0.95±0.02 and CFFF by 42.5±0.2 Hz (p<0,05). The mean central retinal thickness decreased reliably down to 265.1±12.1 µm (p<0.05). Light sensitivity of the macula improved and scored 24.13±12.3 dB (p<0.05). In group 2, the mean central retinal thickness appeared to be 383.1±221 µm, which was reliably higher than that in healthy individuals (p<0.05) and in type 2 diabetes patients without diabetic retinopathy (DR 0) (p<0.05). Tear assessment 12 months after the treatment revealed a significant decrease in VEGF-A and MCP-1 concentrations - down to 655.1±86.1 pg/ml and 1133 pg/ml, respectively (p<0.05). CONCLUSION: Conservative treatment with calcium dobesilate has proved effective in patients with DR I without DME as it ensures improvement and stabilization of the state of the retina (clinical and morphological) in one month already (judging from FAG and OCT findings). Laser treatment is rational in DR I, DR II, and DR III patients, whose condition is complicated with DME. Improvement and stabilization take, however, longer to be achieved - up to 1 year (according to FAG and OCT). Tear fluid assessment for particular participants in disease pathogenesis, such as VEGF-A and MCP-1, is a unique method for disease control and patient follow-up with account to different treatments. A new method for predicting the progression of diabetic retinopathy and diabetic macular edema has been suggested (RF patent for invention â„–2520826).
Publication type:JOURNAL ARTICLE
Name of substance:0 (Chemokine CCL2); 0 (Eye Proteins); 0 (Hemostatics); 0 (Peptide Fragments); 0 (Vascular Endothelial Growth Factor A); 0 (monocyte chemoattractant protein 1 (66-77)); 0 (tear proteins); 5921X1560Q (Calcium Dobesilate)


  4 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:27379855
Author:Pavlovic MD
Address:Dermatologiezentrum Parmova, Parmova 53, 1000, Ljubljana, Slowenien. milos.pavlovic@dcp.si.
Title:Medikamentöse Behandlung chronischer Venenerkrankungen. [Drug Treatment of Chronic Venous Diesease].
Source:Wien Med Wochenschr; 166(9-10):312-9, 2016 Jun.
ISSN:1563-258X
Country of publication:Austria
Language:ger
Abstract:Chronic venous disease (CVD) affects at least 15-25 % of the general population incurring not only high morbidity but also considerable economical burden. The mainstay of modern treatment of CVD are endovenous therapeutic procedures and compression therapy. As far as the pathogenesis of CVD is being gradually unraveled the interest in drugs able to impact the process is growing. Here we have presented an overview of a majority of oral preparations used so far to treat CVD including venous leg ulcers. After several decades of clinical use a few flavonoid preparations, in the first place micronized purified flavonoid fraction, collected enough evidence to recommend them as a short-term adjunct treatment of CVD. However, other compounds are also promising in this regards. Yet, we need more larger and longer-term clinical trials to more precisely define effects, cost-effectiveness and, above all, capacity for prophylactic application of the drugs. Learning more about basis of CVD will help design new drugs directed at specific aspects of the disease process.
Publication type:JOURNAL ARTICLE
Name of substance:0 (Coumarins); 0 (Flavonoids); 5921X1560Q (Calcium Dobesilate)


  5 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PMID:27249620
Author:Seker A; Bardakci O; Eryilmaz S; Kocarslan S; Incebiyik A; Yucel Y; Taskin A; Soyalp M; Gokalp O; Uzunkoy A
Address:Department of General Surgery, Harran University, Faculty of Medicine, Sanliurfa, Turkey. drsekerahmet@hotmail.com.
Title:Does calcium dobesilate protect against intestinal ischemia-reperfusion injury induced in rats?
Source:Eur Rev Med Pharmacol Sci; 20(10):2168-73, 2016 May.
ISSN:2284-0729
Country of publication:Italy
Language:eng
Abstract:OBJECTIVE: In this study, we investigated whether the administration of calcium dobesilate (CD) affects oxidative stress markers and histopathological outcomes in a rat model of intestinal ischemia-reperfusion (IR) injury. MATERIALS AND METHODS: This study was conducted with 30 male Wistar rats. The rats were randomly assigned to three groups as follows: a sham group (n = 10), an IR group (n = 10), and an IR + CD group (n = 10). In the sham group, superior mesenteric artery (SMA) dissection alone was performed during laparotomy. In the IR group, the procedure included SMA occlusion for 60 min, followed by reperfusion for 60 min. In the IR + CD group, CD (100 mg/kg/day) was additionally given for two days before laparotomy by intragastric lavage. In all the rats, 2 ml of blood were drawn, and an ileal segment (approximately 2 cm in size) was removed to evaluate oxidative stress markers. The ileal segment removed was divided into two pieces, and one piece was reserved for histopathological evaluation. RESULTS: Compared to the other groups, both serum and tissue oxidative stress indices were lower in the IR + CD group. The decrease was due to CD increasing the total antioxidant capacity. Moreover, the histological analysis showed that CD reduced tissue injury. CONCLUSIONS: CD may exert a protective effect against intestinal IR injury by increasing antioxidant capacity.
Publication type:JOURNAL ARTICLE
Name of substance:0 (Antioxidants); 0 (Hemostatics); 5921X1560Q (Calcium Dobesilate)


  6 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Stein, Airton T
Full text
Texto completo
PMID:27048768
Author:Martinez-Zapata MJ; Vernooij RW; Uriona Tuma SM; Stein AT; Moreno RM; Vargas E; Capellà D; Bonfill Cosp X
Address:Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP), Sant Antoni Maria Claret 167, Pavilion 18, Barcelona, Catalunya, Spain, 08025.
Title:Phlebotonics for venous insufficiency.
Source:Cochrane Database Syst Rev; 4:CD003229, 2016 Apr 06.
ISSN:1469-493X
Country of publication:England
Language:eng
Abstract:BACKGROUND: Chronic venous insufficiency (CVI) is a common condition caused by valvular dysfunction with or without associated obstruction, usually in the lower limbs. It might result in considerable discomfort with symptoms such as pain, itchiness and tiredness in the legs. Patients with CVI may also experience swelling and ulcers. Phlebotonics are a class of drugs often used to treat CVI. This is an update of a review first published in 2005. OBJECTIVES: To assess the efficacy and safety of phlebotonics administered both orally and topically for treatment of signs and symptoms of lower extremity CVI. SEARCH METHODS: For this update, the Cochrane Vascular Trials Search Co-ordinator (TSC) searched the Specialised Register (August 2015), as well as the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7). The reference lists of the articles retrieved by electronic searches were searched for additional citations. We also contacted pharmaceutical companies and searched the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal for ongoing studies (last searched in August 2015). SELECTION CRITERIA: Randomised, double-blind, placebo-controlled trials (RCTs) assessing the efficacy of rutosides, hidrosmine, diosmine, calcium dobesilate, chromocarbe, Centella asiatica, disodium flavodate, french maritime pine bark extract, grape seed extract and aminaftone in patients with CVI at any stage of the disease. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed the quality of included RCTs. We estimated the effects of treatment by using risk ratios (RRs), mean differences (MDs) and standardised mean differences (SMDs), according to the outcome assessed. We calculated 95% confidence interval (CIs) and percentage of heterogeneity (I(2)). Additionally, we performed sensitivity analyses. MAIN RESULTS: We included 66 RCTs of oral phlebotonics, but only 53 trials provided quantifiable data (involving 6013 participants; mean age 50 years) for the efficacy analysis: 28 for rutosides, 10 hidrosmine and diosmine, nine calcium dobesilate, two Centella asiatica, two aminaftone, two french maritime pine bark extract and one grape seed extract. No studies evaluating topical phlebotonics, chromocarbe, naftazone or disodium flavodate fulfilled the inclusion criteria.Moderate-quality evidence suggests that phlebotonics reduced oedema in the lower legs compared with placebo. Phlebotonics showed beneficial effects among participants including reduced oedema (RR 0.70, 95% CI 0.63 to 0.78; I(2) = 20%; 1245 participants) and ankle circumference (MD -4.27 mm, 95% CI -5.61 to -2.93 mm; I(2) = 47%; 2010 participants). Low-quality evidence reveals no difference in the proportion of ulcers cured with phlebotonics compared with placebo (RR 0.94, 95% CI 0.79 to 1.13; I(2) = 5%; 461 participants). In addition, phlebotonics showed greater efficacy for trophic disorders, cramps, restless legs, swelling and paraesthesia, when compared with placebo. We identified heterogeneity for the variables of pain, itching, heaviness, quality of life and global assessment by participants. For quality of life, it was not possible to pool the studies because heterogeneity was high. However, high-quality evidence suggests no differences in quality of life for calcium dobesilate compared with placebo (MD -0.60, 95% CI -2.15 to 0.95; I(2) = 40%; 617 participants), and low-quality evidence indicates that in the aminaftone group, quality of life was improved over that reported in the placebo group (MD -10.00, 95% CI -17.01 to - 2.99; 79 participants). Moderate-quality evidence shows that the phlebotonics group had greater risk of non-severe adverse events than the placebo group (RR 1.21, 95% CI 1.05 to 1.41; I(2) = 0; 3975 participants). Gastrointestinal disorders were the most frequently reported adverse events. AUTHORS' CONCLUSIONS: Moderate-quality evidence shows that phlebotonics may have beneficial effects on oedema and on some signs and symptoms related to CVI such as trophic disorders, cramps, restless legs, swelling and paraesthesia when compared with placebo but can produce more adverse effects. Phlebotonics showed no differences compared with placebo in ulcer healing. Additional high-quality RCTs focused on clinically important outcomes are needed to improve the evidence base.
Publication type:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
Name of substance:0 (Hematologic Agents); 0 (Plant Extracts); 0 (para-Aminobenzoates); 03JLX11PE9 (aminaftone); 4I5K8199OQ (hidrosmin); 5921X1560Q (Calcium Dobesilate); 5G06TVY3R7 (Rutin); 7QM776WJ5N (Diosmin); TL2TJE8QTX (4-Aminobenzoic Acid)


  7 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text
PMID:25991692
Author:Rabe E; Ballarini S; Lehr L; Doxium EDX09/01 Study Group
Address:Department of Dermatology, Rheinische Friedrich-Wilhelms University, Bonn, Germany eberhard.rabe@ukb.uni-bonn.de.
Title:A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency.
Source:Phlebology; 31(4):264-74, 2016 May.
ISSN:1758-1125
Country of publication:England
Language:eng
Abstract:OBJECTIVE: To show the superiority of 500 mg calcium dobesilate vs. placebo in reduction of edema of the lower limbs in patients with chronic venous insufficiency, Clinical, Etiological, Anatomical and Pathophysiological classes C3/C4. METHODS: A total of 351 patients were randomized (n = 174 calcium dobesilate, n = 177 placebo). Active treatment was 500 mg calcium dobesilate, three times daily for 12 weeks, with a 12-week follow-up. RESULTS: At the end of treatment, the relative volume change in the most pathological leg was -0.6 ± 4.8% with calcium dobesilate compared to -0.3 ± 3.3% with placebo (p = 0.09). At the end of follow-up, this was -1.01 ± 5.4% for calcium dobesilate vs. -0.08 ± 3.5% for placebo (p = 0.002). CONCLUSIONS: Calcium dobesilate treatment resulted in no significant volume change in the most pathological leg between baseline and end of treatment. However, the calcium dobesilate group showed a significantly greater volume decrease in the most pathological leg at the end of follow-up. Calcium dobesilate was well-tolerated, with a safety profile consistent with previously published data.
Publication type:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
Name of substance:5921X1560Q (Calcium Dobesilate)


  8 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text
PMID:26061311
Author:Guo X; Hou L; Cheng X; Zhang T; Yu S; Fang H; Xia L; Qi Z; Qin X; Zhang L; Liu Q; Liu L; Chi S; Hao Y; Qiu L
Address:From the Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academic Medical Science and Peking Union Medical College (XG, LH, XC, SY, HF, LX, ZQ, XQ, LZ, QL, LL, SC, YH, LQ); and Beijing Hospital, National Center for Clinical Laboratories, Ministry of Health, Beijing, PR China (TZ).
Title:Strong Negative Interference by Calcium Dobesilate in Sarcosine Oxidase Assays for Serum Creatinine Involving the Trinder Reaction.
Source:Medicine (Baltimore); 94(23):e905, 2015 Jun.
ISSN:1536-5964
Country of publication:United States
Language:eng
Abstract:The vasoprotective drug calcium dobesilate is known to interfere with creatinine (Cr) quantifications in sarcosine oxidase enzymatic (SOE) assays. The aim of this study was to investigate this interference in 8 different commercially available assays and to determine its clinical significance. In in vitro experiments, interference was evaluated at 3 Cr levels. For this, Cr was quantified by SOE assays in pooled serum supplemented with calcium dobesilate at final concentrations of 0, 2, 4, 8, 16, 32, and 64 µg/mL. Percent bias was calculated relative to the drug-free specimen. For in vivo analyses, changes in serum concentrations of Cr, cystatin C (CysC; a renal function marker), and calcium dobesilate were monitored in healthy participants of group I before and after oral calcium dobesilate administration. In addition, variations in interference were also examined among different SOE assays using serum obtained from healthy participants of group II. Lastly, Cr levels from the 10 patients treated with calcium dobesilate were measured using 4 SOE assays and liquid chromatography-isotope dilution tandem mass spectrometry (LC-IDMS/MS) for comparison. Our in vitro analyses indicated that the presence of 8 µg/mL calcium dobesilate resulted in a -4.4% to -36.3% reduction in Cr serum concentration compared to drug-free serum for 8 SOE assays examined. In vivo, Cr values decreased relative to the baseline level with increasing drug concentration, with the lowest Cr levels obtained at 2 or 3 hours after drug administration in participants of group I. The observed Cr concentrations for participants in group II were reduced by -28.5% to -3.1% and -60.5% to -11.6% at 0 and 2 hours after administration related to baseline levels. The Cr values of 10 patients measured by Roche, Beckman, Maker, and Merit Choice SOE assays showed an average deviation of -20.0%, -22.4%, -14.2%, and -29.6%, respectively, compared to values obtained by LC-IDMS/MS. These results revealed a clinically significant negative interference with calcium dobesilate in all sarcosine oxidase-based Cr assays, but the degree of interference varied greatly among the assays examined. Thus, extra care should be taken in evaluating Cr quantification obtained by SOE assays in patients undergoing calcium dobesilate therapy.
Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
Name of substance:5921X1560Q (Calcium Dobesilate); AYI8EX34EU (Creatinine); EC 1.5.3.1 (Sarcosine Oxidase)


  9 / 227 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
PMID:25989912
Author:Simó R; Ballarini S; Cunha-Vaz J; Ji L; Haller H; Zimmet P; Wong TY
Address:Diabetes and Metabolism Reseach Unit. Vall d'Hebron Research Institute. Universitat Autonoma de Barcelona and Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII). Barcelona, Spain Pg. Vall d'Hebron 119-129. 08035 Barcelona, Spain. rafael.simo@vhir.org.
Title:Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.
Source:Curr Med Chem; 22(21):2580-9, 2015.
ISSN:1875-533X
Country of publication:Netherlands
Language:eng
Abstract:The rapid escalation in the global prevalence diabetes, with more than 30% being afflicted with diabetic retinopathy (DR), means it is likely that associated vision-threatening conditions will also rise substantially. This means that new therapeutic approaches need to be found that go beyond the current standards of diabetic care, and which are effective in the early stages of the disease. In recent decades several new pharmacological agents have been investigated for their effectiveness in preventing the appearance and progression of DR or in reversing DR; some with limited success while others appear promising. This up-to-date critical review of non-traditional systemic treatments for DR is based on the published evidence in MEDLINE spanning 1980-December 2014. It discusses a number of therapeutic options, paying particular attention to the mechanisms of action and the clinical evidence for the use of renin-angiotensin system blockade, fenofibrate and calcium dobesilate monohydrate in DR.
Publication type:JOURNAL ARTICLE; REVIEW
Name of substance:5921X1560Q (Calcium Dobesilate); U202363UOS (Fenofibrate)


  10 / 227 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text
PMID:25528255
Author:Zhang X; Liu W; Wu S; Jin J; Li W; Wang N
Address:Beijing Institute of Ophthalmology, Tongren Eye Centre, Tongren Hospital, Capital Medical University, Beijing, 100730, China, mmzxy2010@163.com.
Title:Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis.
Source:Sci China Life Sci; 58(1):101-7, 2015 Jan.
ISSN:1869-1889
Country of publication:China
Language:eng
Abstract:Many randomized clinical controlled trials have confirmed the efficacy and safety of calcium dobesilate in treating diabetic retinopathy (DR). This systematic review critically evaluated the evidence that links calcium dobesilate to DR. In this fixed-effects meta-analysis, a total of 221 pertinent English-language articles published between January 1975 and October 2013 were identified. Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were conducted using the keywords "diabetic retinopathy" and "calcium dobesilate". The extracted information included the study design, inclusion and exclusion criteria, setting, sample size, participant mean age, treatment regime, mean change in best corrected visual acuity, laboratory parameters, capillary fragility, intraocular pressure and fundus manifestations based on the findings of fluorescent angiography. The summary statistics indicated that calcium dobesilate was significantly associated with improving retinal microaneurysms (RR: 0.62, 95%CI: 0.42-0.90, P=0.01), retinal hemorrhages (RR: 0.39, 95% CI: 0.17-0.88, P=0.02); exudates (RR: 0.31, 95% CI: 0.12-0.81, P=0.02), reduction of whole blood viscosity (MD: -0.57 CP, 95% CI: -0.75 to -0.38, P<0.001), plasma viscosity (MD: -0.36 CP, 95% CI: -0.63 to -0.09, P=0.01) and blood cholesterol (MD: -0.48 mg mL(-1), 95% CI: -0.64-0.33, P<0.00001). Intraocular pressure was also significantly reduced (MD: -5.59 mmHg, 95% CI: -6.69 to -4.50, P<0.00001). The results indicate that calcium dobesilate effectively treats DR at the systematic and local ocular levels.
Publication type:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
Name of substance:5921X1560Q (Calcium Dobesilate)



page 1 of 23 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information